Literature DB >> 19804409

Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics.

Anett Stephan1, Michael Wermann, Alex von Bohlen, Birgit Koch, Holger Cynis, Hans-Ulrich Demuth, Stephan Schilling.   

Abstract

Glutaminyl cyclases (QCs) catalyze the formation of pyroglutamate residues at the N-terminus of several peptides and proteins from plants and animals. Recently, isoenzymes of mammalian QCs have been identified. In order to gain further insight into the biochemical characteristics of isoQCs, the human and murine enzymes were expressed in the secretory pathway of Pichia pastoris. Replacement of the N-terminal signal anchor by an alpha-factor prepropeptide from Saccharomyces cerevisiae resulted in poor secretion of the protein. Insertion of an N-terminal glycosylation site and shortening of the N-terminus improved isoQC secretion 100-fold. A comparison of different recombinant isoQC proteins did not reveal an influence of mutagenic changes on catalytic activity. An initial characterization showed identical modes of substrate conversion of human isoQC and murine isoQC. Both proteins displayed a broad substrate specificity and preference for hydrophobic substrates, similar to the related QC. Likewise, a determination of the zinc content and reactivation of the apo-isoQC revealed equimolar zinc present in QC and isoQC. Far-UV CD spectroscopic analysis of murine QC and isoQC indicated virtually identical structural components. The present investigation provides the first enzymatic characterization of mammalian isoQCs. QC and isoQC represent very similar proteins, which are both present in the secretory pathway of cells. The functions of QCs and isoQC probably complement each other, suggesting a pivotal role of pyroglutamate modification for protein and peptide maturation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804409     DOI: 10.1111/j.1742-4658.2009.07337.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  11 in total

1.  Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding.

Authors:  Kai-Fa Huang; Su-Sen Liaw; Wei-Lin Huang; Cho-Yun Chia; Yan-Chung Lo; Yi-Ling Chen; Andrew H-J Wang
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

2.  Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.

Authors:  Sadim Jawhar; Oliver Wirths; Stephan Schilling; Sigrid Graubner; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-12-10       Impact factor: 5.157

3.  2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.

Authors:  Eunsun Park; Kyung-Hee Song; Darong Kim; Minyoung Lee; Nguyen Van Manh; Hee Kim; Ki Bum Hong; Jeewoo Lee; Jie-Young Song; Soosung Kang
Journal:  ACS Med Chem Lett       Date:  2022-08-16       Impact factor: 4.632

4.  Glutaminyl cyclases as novel targets for the treatment of septic arthritis.

Authors:  Annelie Hellvard; Katarzyna Maresz; Stephan Schilling; Sigrid Graubner; Ulrich Heiser; Roland Jonsson; Holger Cynis; Hans-Ulrich Demuth; Jan Potempa; Piotr Mydel
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

5.  Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.

Authors:  Holger Cynis; Lydiane Funkelstein; Thomas Toneff; Charles Mosier; Michael Ziegler; Birgit Koch; Hans-Ulrich Demuth; Vivian Hook
Journal:  Neurodegener Dis       Date:  2014-06-18       Impact factor: 2.977

6.  The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions.

Authors:  Holger Cynis; Torsten Hoffmann; Daniel Friedrich; Astrid Kehlen; Kathrin Gans; Martin Kleinschmidt; Jens-Ulrich Rahfeld; Raik Wolf; Michael Wermann; Anett Stephan; Monique Haegele; Reinhard Sedlmeier; Sigrid Graubner; Wolfgang Jagla; Anke Müller; Rico Eichentopf; Ulrich Heiser; Franziska Seifert; Paul H A Quax; Margreet R de Vries; Isabel Hesse; Daniela Trautwein; Ulrich Wollert; Sabine Berg; Ernst-Joachim Freyse; Stephan Schilling; Hans-Ulrich Demuth
Journal:  EMBO Mol Med       Date:  2011-07-20       Impact factor: 12.137

7.  Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.

Authors:  Maike Hartlage-Rübsamen; Alexander Waniek; Juliane Meissner; Markus Morawski; Stephan Schilling; Carsten Jäger; Martin Kleinschmidt; Holger Cynis; Astrid Kehlen; Thomas Arendt; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2015-02-11       Impact factor: 17.088

8.  N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity.

Authors:  Astrid Kehlen; Monique Haegele; Livia Böhme; Holger Cynis; Torsten Hoffmann; Hans-Ulrich Demuth
Journal:  Biosci Rep       Date:  2017-08-23       Impact factor: 3.840

9.  A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.

Authors:  Inge Lues; Frank Weber; Antje Meyer; Uli Bühring; Torsten Hoffmann; Kerstin Kühn-Wache; Susanne Manhart; Ulrich Heiser; Rolf Pokorny; Joseph Chiesa; Konrad Glund
Journal:  Alzheimers Dement (N Y)       Date:  2015-10-03

10.  MiR-205-5p/GGCT Attenuates Growth and Metastasis of Papillary Thyroid Cancer by Regulating CD44.

Authors:  Han-Ning Li; Hui-Min Zhang; Xing-Rui Li; Jun Wang; Tao Xu; Shu-Yu Li; Meng-Lu Dong; Ge Wang; Xiao-Qing Cui; Xue Yang; Yong-Lin Wu; Xing-Hua Liao; Ya-Ying Du
Journal:  Endocrinology       Date:  2022-04-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.